The Tryptophan System in Cocaine-Induced Depression.
Francina FonsecaJoan Ignasi Mestre-PintóÀlex Gómez-GómezDiana Martinez-SanvisensRocío Rodríguez-MinguelaEsther PapaseitClara Pérez-MañáKlaus LangohrOlga ValverdeÓscar J PozoMagi FarréMarta Torrensnull On Behalf Of Neurodep GroupPublished in: Journal of clinical medicine (2020)
Major depression disorder (MDD) is the most prevalent psychiatric comorbid condition in cocaine use disorder (CUD). The comorbid MDD might be primary-MDD (CUD-primary-MDD) or cocaine-induced MDD (CUD-induced-MDD), and their accurate diagnoses and treatment is a challenge for improving prognoses. This study aimed to assess the tryptophan/serotonin (Trp/5-HT) system with the acute tryptophan depletion test (ATD), and the kynurenine pathway in subjects with CUD-primary-MDD, CUD-induced-MDD, MDD and healthy controls. The ATD was performed with a randomized, double-blind, crossover, and placebo-controlled design. Markers of enzymatic activity of indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase, kynurenine aminotransferase (KAT) and kynureninase were also established. Following ATD, we observed a decrease in Trp levels in all groups. Comparison between CUD-induced-MDD and MDD revealed significant differences in 5-HT plasma concentrations (512 + 332 ng/mL vs. 107 + 127 ng/mL, p = 0.039) and the Kyn/5-HT ratio (11 + 15 vs. 112 + 136; p = 0.012), whereas there were no differences between CUD-primary-MDD and MDD. Effect size coefficients show a gradient for all targeted markers (d range 0.72-1.67). Results suggest different pathogenesis for CUD-induced-MDD, with lower participation of the tryptophan system, probably more related to other neurotransmitter pathways and accordingly suggesting the need for a different pharmacological treatment approach.
Keyphrases
- major depressive disorder
- high glucose
- bipolar disorder
- diabetic rats
- drug induced
- clinical trial
- oxidative stress
- randomized controlled trial
- endothelial cells
- depressive symptoms
- high resolution
- mental health
- hepatitis b virus
- liver failure
- drug delivery
- intensive care unit
- study protocol
- cancer therapy
- open label
- mass spectrometry
- respiratory failure
- phase ii study